Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by StockNews.com

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report sent to investors on Wednesday morning. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Performance

ADXS stock opened at $0.03 on Wednesday. The company has a market capitalization of $1.15 million, a P/E ratio of 0.00 and a beta of 1.70. The company has a fifty day moving average price of $0.05 and a 200-day moving average price of $0.10. Ayala Pharmaceuticals has a 52-week low of $0.00 and a 52-week high of $1.49.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.